Options de traitement topique du champ de cancérisation
Résumé
Le concept de champ de cancérisation (CC) a été décrit pour la première fois par Slaughter et coll. en 1953. Dans cette étude, des atypies pathologiques ont été observées dans le tissu épithélial d’apparence normale adjacent aux carcinomes oropharyngés. Plusieurs nouvelles tumeurs primaires se sont ensuite développées dans ce champ.
Plus tard, les recherches ont défini le CC au niveau cellulaire comme étant la croissance d’un clone mutant qui crée un champ de cellules prédisposées à une croissance tumorale ultérieure. Le champ de cancérisation cutané se développe dans les zones exposées à un rayonnement ultraviolet (UV) chronique qui entraîne l’apparition de champs de proliférations clonales de kératinocytes porteurs de mutations p53. Il se caractérise par la présence de kératoses actiniques (KA) multifocales, de carcinomes épidermoïdes in situ (CEis) et de carcinomes épidermoïdes cutanés (CEC). Les facteurs de risque du CC sont similaires à ceux des KA et des CEC, notamment l’exposition aux UV, une peau claire, l’âge avancé, le sexe masculin et l’immunosuppression. Le CC cutané est localisé sur les zones corporelles très souvent exposées au soleil, notamment le visage, le cuir chevelu touché par la calvitie, les avant-bras et la partie dorsale des mains.
Références
Slaughter DP, Southwick HW, Smejkal W. “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer. 1953 Sep;6(5):963-8.
Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res. 2003;63:1727-1730.
Willenbrink TJ, Ruiz ES, Cornejo CM, Schmults CD, Arron ST, Jambusaria-Pahlajani A. Field cancerization: Definition, epidemiology, risk factors, and outcomes. J Am Acad Dermatol. 2020 Sep;83(3):709-717.
Rigel DS. Cutaneous ultraviolet exposure and its relationship to the development of skin cancer. J Am Acad Dermatol. 2008;58(5):S129-32.
Non-Melanoma Skin Cancer. Public Health Agency of the Government of Canada. https://www.canada.ca/en/public-health/services/chronic-diseases/cancer/non-melanoma-skin-cancer.html. Published December 9, 2019. Accessed September 25, 2022.
Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A. The natural history of actinic keratosis: a systematic review. Br J Dermatol, 169 (2013), pp. 502-518
Neugebauer R, Levandoski KA, Zhu Z, et al. A real-world, community-based cohort study comparing the effectiveness of topical fluorouracil versus topical imiquimod for the treatment of actinic keratosis. J Am Acad Dermatol. 2018;78:710-716.
Pomerantz H, Hogan D, Eilers D, et al. Long-term efficacy of topical fluorouracil cream, 5%, for treating actinic keratosis: a randomized clinical trial. JAMA Dermatol. 2015;151:952-960.
Steeb T, Wessely A, Schmitz L, et al. Interventions for Actinic Keratosis in Nonscalp and Nonface Localizations: Results from a Systematic Review with Network Meta-Analysis. J Invest Dermatol. 2021;141(2):345-354.e8.
Eisen DB, Asgari MM, Bennett DD et al. Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2021 Oct 1;85(4):e209-33.
Askew DA, Mickan SM, Soyer HP, Wilkinson D. Effectiveness of 5-fluorouracil treatment for actinic keratosis a systematic review of randomized controlled trials. Int J Dermatol. 2009;48:453-463.
Cornejo CM, Jambusaria-Pahlajani A, Willenbrink TJ, Schmults CD, Arron ST, Ruiz ES. Field cancerization: Treatment. J Am Acad Dermatol. 2020 Sep;83(3):719-730.
Cunningham TJ, Tabacchi M, Eliane JP, et al. Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. J Clin Invest. 2017;127(1):106-116. doi:10.1172/JCI89820
Mohney L, Singh R, Grada A, Feldman S. Use of Topical Calcipotriol Plus 5-Fluorouracil in the Treatment of Actinic Keratosis: A Systematic Review. J Drugs Dermatol. 2022;21(1):60-65. doi:10.36849/JDD.2022.6632
Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol. 2006 Jun;126(6):1251-5.
Henderson BW, Dougherty TJ. How does photodynamic therapy work?. Photochem Photobiol. 1992;55(1):145-157.
Galderma Canada Inc. Metvix (methyl aminolevulinate topical cream) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00038693.PDF . Revised March 30, 2017. Accessed September 22, 2022.
Clarion Medical Technologies Inc. Levulan Kerastick [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00027478.PDF. Revised September 30, 2014. Accessed September 22, 2022.
Tschen EH, Wong DS, Pariser DM, et al. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol. 2006;155(6):1262-1269.
Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol. 2008;18(5):547-553.
Ibbotson SH, Wong TH, Morton CA, et al. Adverse effects of topical photodynamic therapy: a consensus review and approach to management. Br J Dermatol. 2019;180(4):715-729.
Lacour JP, Ulrich C, Gilaberte Y, et al. Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe. J Eur Acad Dermatol Venereol. 2015;29(12):2342-2348.
Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol. 2002 Jan;146(1):94-100.
Miller AC, Adjei S, Temiz LA, Tyring SK. Tirbanibulin for the Treatment of Actinic Keratosis: A Review. Skin Therapy Lett. 2022;27(4):4-7.
Blauvelt A, Kempers S, Lain E, et al. Phase 3 Trials of tirbanibulin ointment for actinic keratosis. N Engl J Med. 2021 Feb 11;384(6):512-20. Slaughter DP, Southwick HW, Smejkal W. “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer. 1953 Sep;6(5):963-8.
Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res. 2003;63:1727-1730.
Willenbrink TJ, Ruiz ES, Cornejo CM, Schmults CD, Arron ST, Jambusaria-Pahlajani A. Field cancerization: Definition, epidemiology, risk factors, and outcomes. J Am Acad Dermatol. 2020 Sep;83(3):709-717.
Rigel DS. Cutaneous ultraviolet exposure and its relationship to the development of skin cancer. J Am Acad Dermatol. 2008;58(5):S129-32.
Non-Melanoma Skin Cancer. Public Health Agency of the Government of Canada. https://www.canada.ca/en/public-health/services/chronic-diseases/cancer/non-melanoma-skin-cancer.html. Published December 9, 2019. Accessed September 25, 2022.
Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A. The natural history of actinic keratosis: a systematic review. Br J Dermatol, 169 (2013), pp. 502-518
Neugebauer R, Levandoski KA, Zhu Z, et al. A real-world, community-based cohort study comparing the effectiveness of topical fluorouracil versus topical imiquimod for the treatment of actinic keratosis. J Am Acad Dermatol. 2018;78:710-716.
Pomerantz H, Hogan D, Eilers D, et al. Long-term efficacy of topical fluorouracil cream, 5%, for treating actinic keratosis: a randomized clinical trial. JAMA Dermatol. 2015;151:952-960.
Steeb T, Wessely A, Schmitz L, et al. Interventions for Actinic Keratosis in Nonscalp and Nonface Localizations: Results from a Systematic Review with Network Meta-Analysis. J Invest Dermatol. 2021;141(2):345-354.e8.
Eisen DB, Asgari MM, Bennett DD et al. Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2021 Oct 1;85(4):e209-33.
Askew DA, Mickan SM, Soyer HP, Wilkinson D. Effectiveness of 5-fluorouracil treatment for actinic keratosis a systematic review of randomized controlled trials. Int J Dermatol. 2009;48:453-463.
Cornejo CM, Jambusaria-Pahlajani A, Willenbrink TJ, Schmults CD, Arron ST, Ruiz ES. Field cancerization: Treatment. J Am Acad Dermatol. 2020 Sep;83(3):719-730.
Cunningham TJ, Tabacchi M, Eliane JP, et al. Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. J Clin Invest. 2017;127(1):106-116. doi:10.1172/JCI89820
Mohney L, Singh R, Grada A, Feldman S. Use of Topical Calcipotriol Plus 5-Fluorouracil in the Treatment of Actinic Keratosis: A Systematic Review. J Drugs Dermatol. 2022;21(1):60-65. doi:10.36849/JDD.2022.6632
Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol. 2006 Jun;126(6):1251-5.
Henderson BW, Dougherty TJ. How does photodynamic therapy work?. Photochem Photobiol. 1992;55(1):145-157.
Galderma Canada Inc. Metvix (methyl aminolevulinate topical cream) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00038693.PDF . Revised March 30, 2017. Accessed September 22, 2022.
Clarion Medical Technologies Inc. Levulan Kerastick [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00027478.PDF. Revised September 30, 2014. Accessed September 22, 2022.
Tschen EH, Wong DS, Pariser DM, et al. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol. 2006;155(6):1262-1269.
Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol. 2008;18(5):547-553.
Ibbotson SH, Wong TH, Morton CA, et al. Adverse effects of topical photodynamic therapy: a consensus review and approach to management. Br J Dermatol. 2019;180(4):715-729.
Lacour JP, Ulrich C, Gilaberte Y, et al. Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe. J Eur Acad Dermatol Venereol. 2015;29(12):2342-2348.
Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol. 2002 Jan;146(1):94-100.
Miller AC, Adjei S, Temiz LA, Tyring SK. Tirbanibulin for the Treatment of Actinic Keratosis: A Review. Skin Therapy Lett. 2022;27(4):4-7.
Blauvelt A, Kempers S, Lain E, et al. Phase 3 Trials of tirbanibulin ointment for actinic keratosis. N Engl J Med. 2021 Feb 11;384(6):512-20.
